Skip to main content

Table 2 Comparison between time points in the total scores of clinical signs

From: Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases

Time

Number of patient (case)

Symptom Score (point)

SD

95% CI

Change from baseline (point)

SD

95% CI

P value*

0 M (BL)

12

14.3

1.09

12.1

16.6

 

0.5 M

12

7.33

1.09

5.06

9.61

7.00

0.80

5.43

8.57

 < .001

1 M

12

7.21

1.09

4.93

9.48

7.13

0.80

5.56

8.69

 < .001

2 M

12

7.63

1.09

5.35

9.90

6.71

0.80

5.14

8.27

 < .001

3 M

12

7.08

1.09

4.81

9.36

7.25

0.80

5.68

8.82

 < .001

6 M

12

5.71

1.09

3.43

7.98

8.63

0.80

7.06

10.2

 < .001

1Y

12

5.54

1.09

3.27

7.82

8.79

0.80

7.23

10.4

 < .001

2Y

12

7.17

1.09

4.89

9.44

7.17

0.80

5.60

8.73

 < .001

3Y

12

6.71

1.09

4.43

8.98

7.63

0.80

6.06

9.19

 < .001

4Y

12

7.00

1.09

4.73

9.27

7.33

0.80

5.77

8.90

 < .001

5Y

12

5.33

1.09

3.06

7.61

9.00

0.80

7.43

10.6

 < .001

6Y

12

5.25

1.09

2.98

7.52

9.08

0.80

7.52

10.6

 < .001

7Y

6

5.59

1.24

3.07

8.11

8.75

0.99

6.80

10.7

 < .001

8Y

5

4.29

1.29

1.68

6.91

10.0

1.05

7.97

12.1

 < .001

9Y

5

4.39

1.29

1.78

7.01

9.94

1.05

7.87

12.0

 < .001

10Y

5

3.49

1.29

0.88

6.11

10.8

1.05

8.77

12.9

 < .001

  1. SD standard deviation, CI confidence intervals, *P value Mixed-effects models